Lupin Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹1133
- Today's High:
- ₹1174.25
- Open Price:
- ₹1135
- 52W Low:
- ₹620.521
- 52W High:
- ₹1143.7
- Prev. Close:
- ₹1127.9
- Volume:
- 158834
Company Statistics
- Market Cap.:
- ₹490.53 billion
- Book Value:
- Revenue TTM:
- ₹0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- ₹0
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 349.41%
Company Profile
Lupin Limited had its IPO on under the ticker symbol 500257.
The company operates in the Other sector and Other industry. Lupin Limited has a staff strength of 0 employees.
Stock update
Shares of Lupin Limited opened at ₹1135 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹1133 - ₹1174.25, and closed at ₹1138.4.
This is a +0.93% increase from the previous day's closing price.
A total volume of 158,834 shares were traded at the close of the day’s session.
In the last one week, shares of Lupin Limited have increased by +3.76%.
Lupin Limited's Key Ratios
Lupin Limited has a market cap of ₹490.53 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Lupin Limited’s revenue was ₹0 with a gross profit of ₹0 and an EBITDA of ₹0. The EBITDA ratio measures Lupin Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lupin Limited’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 349.41%.
In Q2, Lupin Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Lupin Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lupin Limited’s profitability.
Lupin Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Lupin Limited stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 18.81%.
Balance sheet and cash flow metrics
- Total Assets
- ₹229.56 billion
- Total Liabilities
- ₹92.65 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 18.81%
Lupin Limited ended 2025 with ₹229.56 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹229.56 billion while shareholder equity stood at ₹124.65 billion.
Lupin Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹92.65 billion in other current liabilities, 910000000.00 in common stock, ₹123.74 billion in retained earnings and ₹22.19 billion in goodwill. Its cash balance stood at ₹12.32 billion and cash and short-term investments were ₹22.89 billion. The company’s total short-term debt was ₹42,165,400,000 while long-term debt stood at ₹275.10 million.
Lupin Limited’s total current assets stands at ₹124.51 billion while long-term investments were ₹0 and short-term investments were ₹9.96 billion. Its net receivables were ₹44.81 billion compared to accounts payable of ₹25.32 billion and inventory worth ₹44.92 billion.
In 2025, Lupin Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Lupin Limited paid ₹0.19 in dividends in 2025.
Other key metrics
- Current Trading Price
- ₹1138.4
- 52-Week High
- ₹1143.7
- 52-Week Low
- ₹620.521
- Analyst Target Price
- ₹
Lupin Limited stock is currently trading at ₹1138.4 per share. It touched a 52-week high of ₹1143.7 and a 52-week low of ₹1143.7. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1025.93 and 200-day moving average was ₹807.01 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Lupin Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system (CNS), gastro-intestinal, anti-infectives, nonsteroidal anti inflammatory drug therapy, anti-TB, and cephalosporins. The company also develops drug delivery technologies; and offers biosimilars for various therapies, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women?s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.